Altair announces positive Stage I results for Atmosphere645 in treating asthma Altair Therapeutics.

Altair announces positive Stage I results for Atmosphere645 in treating asthma Altair Therapeutics, Inc successful first day http://vardenafilcanadian.com ., a privately-held, biopharmaceutical organization developing novel therapeutics for respiratory diseases, today announced positive results from a stage I multiple dose security and pharmacokinetic study of its lead item, once-weekly inhaled AIR645 in healthful adults and moderate asthmatics. Today by Dr The results were presented. Michael Hodges, M.D., Chief Medical Officer for Altair Therapeutics at the European Respiratory Culture Annual Congress in Vienna. Atmosphere645 is a nonsteroidal dual inhibitor of cellular responses to interleukin -4 and IL-13.

Other entries from category "ozone therapy":

Random entries